438554-23-5 Usage
Uses
Used in Pharmaceutical Industry:
1H-Imidazole-2-carbothioic acid amide is used as an intermediate in the synthesis of pharmaceuticals for its chelating and metal complexing properties, which can enhance the efficacy and stability of certain medications.
Used in Agrochemical Industry:
1H-Imidazole-2-carbothioic acid amide is used as an intermediate in the synthesis of agrochemicals, where its chelating and metal complexing properties can improve the performance and effectiveness of agricultural products.
Used in Antifungal Applications:
1H-Imidazole-2-carbothioic acid amide is used as a potential medication for treating fungal infections due to its antifungal properties. Further research is required to explore its full medicinal potential and applications in this area.
Check Digit Verification of cas no
The CAS Registry Mumber 438554-23-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,8,5,5 and 4 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 438554-23:
(8*4)+(7*3)+(6*8)+(5*5)+(4*5)+(3*4)+(2*2)+(1*3)=165
165 % 10 = 5
So 438554-23-5 is a valid CAS Registry Number.
438554-23-5Relevant academic research and scientific papers
Benzimidazole and pyridylimidazole derivatives
-
, (2008/06/13)
This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
